Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,490.99
(
-0.04%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: mcbio post# 114769

Monday, 02/14/2011 10:01:08 PM

Monday, February 14, 2011 10:01:08 PM

Post# of 257265
There's not much development cost left. Oral Relistor, that's it. Most cost left will be commercialization cost. SLXP is the best choice for PGNX. Relistor is a specialty pharma product, not big pharma product. PGNX wasn't in strong position to demand better term.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today